AP2948A - Thienopyrmidinedione derivatives as TRPA1 modulators - Google Patents

Thienopyrmidinedione derivatives as TRPA1 modulators

Info

Publication number: AP2948A
Authority: AP; ARIPO
Prior art keywords: thienopyrmidinedione; derivatives; trpa1 modulators; trpa1; modulators
Prior art date: 2009-03-23

Application number

AP2011005889A

Other languages

English (en)

Other versions

AP2011005889A0 (en

Inventor

Neelima Khairatkar-Joshi

Sukeerthi Kumar

Sanjay Margal

Original Assignee

Glenmark Pharamceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-23

Filing date

2010-03-23

Publication date

2014-07-31

2010-03-23 Application filed by Glenmark Pharamceuticals Sa filed Critical Glenmark Pharamceuticals Sa

2011-10-31 Publication of AP2011005889A0 publication Critical patent/AP2011005889A0/xx

2014-07-31 Application granted granted Critical

2014-07-31 Publication of AP2948A publication Critical patent/AP2948A/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AP2011005889A 2009-03-23 2010-03-23 Thienopyrmidinedione derivatives as TRPA1 modulators AP2948A (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
IN665MU2009		2009-03-23
US17135509P	2009-04-21	2009-04-21
IN2213MU2009		2009-09-23
US25199409P	2009-10-15	2009-10-15
IN2906MU2009		2009-12-16
US29447010P	2010-01-12	2010-01-12
PCT/IB2010/000930 WO2010109334A2 (en)	2009-03-23	2010-03-23	Thienopyrimidinedione derivatives as trpa1 modulators

Publications (2)

Publication Number	Publication Date
AP2011005889A0 AP2011005889A0 (en)	2011-10-31
AP2948A true AP2948A (en)	2014-07-31

Family

ID=42780205

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2011005889A AP2948A (en)	2009-03-23	2010-03-23	Thienopyrmidinedione derivatives as TRPA1 modulators

Country Status (23)

Country	Link
US (4)	US20120178766A1 (xx)
EP (3)	EP2411395B1 (xx)
JP (2)	JP2012521406A (xx)
KR (2)	KR20110128898A (xx)
CN (3)	CN102361874A (xx)
AP (1)	AP2948A (xx)
AU (2)	AU2010227225A1 (xx)
BR (2)	BRPI1013705A2 (xx)
CA (2)	CA2756535A1 (xx)
DK (3)	DK2411395T3 (xx)
EA (2)	EA201190138A1 (xx)
ES (3)	ES2424341T3 (xx)
HK (2)	HK1166074A1 (xx)
HU (1)	HUE024538T2 (xx)
IL (2)	IL215175A (xx)
MX (1)	MX2011009822A (xx)
PE (2)	PE20120834A1 (xx)
PL (3)	PL2411395T3 (xx)
PT (3)	PT2411395E (xx)
SG (4)	SG184767A1 (xx)
SI (3)	SI2411395T1 (xx)
WO (2)	WO2010109329A1 (xx)
ZA (2)	ZA201107650B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2411395T3 (pl)	2009-03-23	2013-10-31	Glenmark Pharmaceuticals Sa	Pochodne furopirymidynodionu jako modulatory TRPA1
PL2411393T3 (pl)	2009-03-23	2014-06-30	Glenmark Pharmaceuticals Sa	Pochodne skondensowanego pirymidynodionu jako modulatory TRPA1
MY159059A (en)	2010-12-20	2016-12-15	Glenmark Pharmaceuticals Sa	2-amino-4-arylthiazole compounds as trpa1 antagonists
EP2520566A1 (en)	2011-05-06	2012-11-07	Orion Corporation	New Pharmaceutical Compounds
MX2013014679A (es) *	2011-06-13	2014-07-14	Glenmark Pharmaceuticals Sa	Tratamiento de trastornos respiratorios usando antagonistas de trpa1.
WO2012176143A1 (en)	2011-06-22	2012-12-27	Glenmark Pharmaceuticals Sa	Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2012176105A1 (en)	2011-06-22	2012-12-27	Glenmark Pharmaceuticals Sa	Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
WO2013014597A1 (en)	2011-07-25	2013-01-31	Glenmark Pharmaceuticals Sa	Pharmaceutical composition comprising a trpa1 antagonist and a steroid
US20140364445A1 (en) *	2011-12-05	2014-12-11	Glenmark Pharmaceuticals S.A.	Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
IN2014MN02467A (xx) *	2012-06-08	2015-07-10	Glenmark Pharmaceuticals Sa
CN104822653B (zh)	2012-10-01	2017-03-08	奥赖恩公司	N‑丙‑2‑炔基甲酰胺衍生物及其作为trpa1拮抗剂的用途
BR112015030341A2 (pt)	2013-06-20	2017-07-25	Glenmark Pharmaceuticals Sa	formulações de nanoparticulado e processo para prepará-las, composição farmacêutica e uso de composto ou seu sal farmaceuticamente aceitável e estabilizante de superfície
MX2016004741A (es) *	2013-10-15	2016-07-26	Glenmark Pharmaceuticals Sa	Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
WO2016023830A1 (en) *	2014-08-11	2016-02-18	Hydra Biosciences, Inc.	Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180342B1 (en) *	2014-08-11	2019-06-26	Hydra Biosciences, Inc.	Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
EP3180345B1 (en) *	2014-08-11	2018-10-10	Hydra Biosciences, Inc.	Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
EP3180337B1 (en) *	2014-08-11	2018-10-10	Hydra Biosciences, Inc.	Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives
US10329265B2 (en)	2014-08-22	2019-06-25	Duke University	TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en)	2014-09-16	2016-03-24	Glenmark Pharmaceuticals S.A.	Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en)	2015-01-09	2022-01-25	Duke University	TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en)	2015-10-09	2017-04-13	Almirall, S.A.	New trpa1 antagonists
WO2017064068A1 (en)	2015-10-14	2017-04-20	Almirall, S.A.	New trpa1 antagonists
CN109310683A (zh) *	2016-04-07	2019-02-05	杜克大学	用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂
EP3592739A1 (en) *	2017-03-07	2020-01-15	H. Hoffnabb-La Roche Ag	Oxadiazole transient receptor potential channel inhibitors
CN109422749B (zh) *	2017-08-21	2023-01-24	重庆医药工业研究院有限责任公司	一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
CN114656480B (zh) *	2022-04-27	2024-01-26	成都施贝康生物医药科技有限公司	噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671875A (zh) *	2022-04-27	2022-06-28	成都施贝康生物医药科技有限公司	新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007073505A2 (en) *	2005-12-22	2007-06-28	Hydra Biosciences, Inc.	Trpa1 inhibitors for treating pain
WO2007108750A1 (en) *	2006-03-22	2007-09-27	Astrazeneca Ab	Pyridopyrimidine derivatives and their use as pde4 inhibitors
WO2009002933A1 (en) *	2007-06-22	2008-12-31	Hydra Biosciences, Inc.	Methods and compositions for treating disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2248231A1 (de)	1972-10-02	1974-04-11	Basf Ag	3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
SE9702001D0 (sv) *	1997-05-28	1997-05-28	Astra Pharma Prod	Novel compounds
DE69912618T2 (de) *	1998-08-28	2004-10-28	Astrazeneca Ab	NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE
ES2193839B1 (es) *	2001-06-22	2005-02-16	Almirall Prodesfarma, S.A.	Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) *	2001-07-28	2001-09-19	Astrazeneca Ab	Novel compounds
AU2003253165A1 (en) *	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidine fused bicyclic metalloproteinase inhibitors
DE60332475D1 (de) *	2002-10-30	2010-06-17	Vertex Pharma	Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen
US6890923B2 (en) *	2002-12-16	2005-05-10	Astrazeneca Ab	Compounds
US7465581B2 (en)	2002-12-18	2008-12-16	The Scripps Research Institute	ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
SE0300119D0 (sv) *	2003-01-17	2003-01-17	Astrazeneca Ab	Novel compounds
CA2536313A1 (en)	2003-08-22	2005-03-03	Takeda Pharmaceutical Company Limited	Fused pyrimidine derivative and use thereof
EP1713815A4 (en)	2004-02-11	2009-03-11	Smithkline Beecham Corp	PTH AGONISTS
WO2005089206A2 (en)	2004-03-13	2005-09-29	Irm Llc	Modulators of ion channel trpa1
US20090062258A1 (en)	2005-02-03	2009-03-05	Takeda Pharmaceutical Company Limited	Fused pyrimidine derivative and use thereof
AU2006278592A1 (en) *	2005-08-04	2007-02-15	Apogee Biotechnology Corporation	Sphingosine kinase inhibitors and methods of their use
WO2007054480A1 (en) *	2005-11-08	2007-05-18	N.V. Organon	2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
WO2007054474A1 (en) *	2005-11-08	2007-05-18	N.V. Organon	2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives useful in treatment of trpv1 related disorders
US20070105920A1 (en) *	2005-11-08	2007-05-10	Akzo Nobel N.V.	2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
AR065081A1 (es)	2007-01-29	2009-05-13	Xenon Pharmaceuticals Inc	Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
CN101711413B (zh) *	2007-06-25	2013-09-04	桑迪士克科技股份有限公司	具有位于存储元件之间的可单独控制的屏蔽板的非易失性存储装置
WO2010004390A1 (en)	2008-06-17	2010-01-14	Glenmark Pharmaceuticals, S.A.	Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en)	2008-06-27	2009-12-30	Hydra Biosciences, Inc.	Methods and compositions for treating disorders
UA103918C2 (xx)	2009-03-02	2013-12-10	Айерем Элелси	N-(гетеро)арил, 2-(гетеро)арилзаміщені ацетаміди для застосування як модуляторів wnt передачі сигналу$n-(гетеро)арил, 2-(гетеро)арилзамещенные ацетамиды для применения как модуляторов wnt передачи сигнала
DK2411397T3 (da)	2009-03-23	2013-08-05	Glenmark Pharmaceuticals Sa	Isothiazol-pyrimidindionderivater som modulatorer af TRPA1
PL2411395T3 (pl)	2009-03-23	2013-10-31	Glenmark Pharmaceuticals Sa	Pochodne furopirymidynodionu jako modulatory TRPA1
US8623880B2 (en)	2009-03-23	2014-01-07	Glenmark Pharmaceuticals S.A.	Fused pyrimidine-dione derivatives as TRPA1 modulators
AR076332A1 (es)	2009-04-21	2011-06-01	Boehringer Ingelheim Int	Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
JP5629324B2 (ja)	2009-10-15	2014-11-19	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジン化合物
US8440710B2 (en)	2009-10-15	2013-05-14	Hoffmann-La Roche Inc.	HSL inhibitors useful in the treatment of diabetes
AR078522A1 (es)	2009-10-15	2011-11-16	Lilly Co Eli	Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
NZ601143A (en)	2010-01-12	2014-10-31	Ab Science	Thiazole and oxazole kinase inhibitors
TWI421250B (zh)	2010-07-13	2014-01-01	Novartis Ag	衍生物及其用於治療神經性疾病之用途

2010
- 2010-03-22 PL PL10716050T patent/PL2411395T3/pl unknown
- 2010-03-22 KR KR1020117022604A patent/KR20110128898A/ko not_active Application Discontinuation
- 2010-03-22 WO PCT/IB2010/000840 patent/WO2010109329A1/en active Application Filing
- 2010-03-22 ES ES10716050T patent/ES2424341T3/es active Active
- 2010-03-22 EP EP10716050.9A patent/EP2411395B1/en not_active Not-in-force
- 2010-03-22 AU AU2010227225A patent/AU2010227225A1/en not_active Abandoned
- 2010-03-22 EA EA201190138A patent/EA201190138A1/ru unknown
- 2010-03-22 SG SG2012069472A patent/SG184767A1/en unknown
- 2010-03-22 DK DK10716050.9T patent/DK2411395T3/da active
- 2010-03-22 BR BRPI1013705A patent/BRPI1013705A2/pt not_active IP Right Cessation
- 2010-03-22 CN CN2010800134701A patent/CN102361874A/zh active Pending
- 2010-03-22 PE PE2011001704A patent/PE20120834A1/es not_active Application Discontinuation
- 2010-03-22 SI SI201030233T patent/SI2411395T1/sl unknown
- 2010-03-22 CA CA2756535A patent/CA2756535A1/en not_active Abandoned
- 2010-03-22 US US13/257,280 patent/US20120178766A1/en not_active Abandoned
- 2010-03-22 JP JP2012501412A patent/JP2012521406A/ja active Pending
- 2010-03-22 SG SG2011066446A patent/SG174398A1/en unknown
- 2010-03-22 PT PT107160509T patent/PT2411395E/pt unknown
- 2010-03-23 ES ES10751712T patent/ES2424342T3/es active Active
- 2010-03-23 PE PE2011001705A patent/PE20120775A1/es active IP Right Grant
- 2010-03-23 CA CA2756536A patent/CA2756536C/en active Active
- 2010-03-23 EP EP10751712.0A patent/EP2411396B1/en active Active
- 2010-03-23 PL PL13002731T patent/PL2634191T3/pl unknown
- 2010-03-23 SI SI201030891T patent/SI2634191T1/sl unknown
- 2010-03-23 DK DK10751712.0T patent/DK2411396T3/da active
- 2010-03-23 HU HUE13002731A patent/HUE024538T2/hu unknown
- 2010-03-23 PT PT107517120T patent/PT2411396E/pt unknown
- 2010-03-23 JP JP2012501414A patent/JP5612070B2/ja active Active
- 2010-03-23 CN CN201080013463.1A patent/CN102361877B/zh active Active
- 2010-03-23 AP AP2011005889A patent/AP2948A/xx active
- 2010-03-23 KR KR1020117022603A patent/KR101524337B1/ko active IP Right Grant
- 2010-03-23 WO PCT/IB2010/000930 patent/WO2010109334A2/en active Application Filing
- 2010-03-23 DK DK13002731T patent/DK2634191T3/en active
- 2010-03-23 CN CN201310628814.5A patent/CN103755720B/zh not_active Expired - Fee Related
- 2010-03-23 US US12/936,451 patent/US8507503B2/en active Active
- 2010-03-23 AU AU2010227230A patent/AU2010227230B2/en active Active
- 2010-03-23 BR BRPI1009381A patent/BRPI1009381B8/pt active IP Right Grant
- 2010-03-23 EA EA201190139A patent/EA022029B1/ru unknown
- 2010-03-23 PL PL10751712T patent/PL2411396T3/pl unknown
- 2010-03-23 MX MX2011009822A patent/MX2011009822A/es unknown
- 2010-03-23 SI SI201030231T patent/SI2411396T1/sl unknown
- 2010-03-23 EP EP13002731.1A patent/EP2634191B1/en active Active
- 2010-03-23 SG SG2011066503A patent/SG174404A1/en unknown
- 2010-03-23 SG SG2012069530A patent/SG184769A1/en unknown
- 2010-03-23 ES ES13002731.1T patent/ES2532386T3/es active Active
- 2010-03-23 PT PT13002731T patent/PT2634191E/pt unknown
2011
- 2011-09-15 IL IL215175A patent/IL215175A/en active IP Right Grant
- 2011-09-15 IL IL215177A patent/IL215177A/en not_active IP Right Cessation
- 2011-10-19 ZA ZA2011/07650A patent/ZA201107650B/en unknown
- 2011-10-19 ZA ZA2011/07649A patent/ZA201107649B/en unknown
2012
- 2012-07-11 HK HK12106784.3A patent/HK1166074A1/xx not_active IP Right Cessation
- 2012-07-11 HK HK12106783.4A patent/HK1166073A1/xx unknown
2013
- 2013-06-25 US US13/925,975 patent/US8987278B2/en active Active
2015
- 2015-02-12 US US14/620,721 patent/US9474758B2/en active Active

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007073505A2 (en) *	2005-12-22	2007-06-28	Hydra Biosciences, Inc.	Trpa1 inhibitors for treating pain
WO2007108750A1 (en) *	2006-03-22	2007-09-27	Astrazeneca Ab	Pyridopyrimidine derivatives and their use as pde4 inhibitors
WO2009002933A1 (en) *	2007-06-22	2008-12-31	Hydra Biosciences, Inc.	Methods and compositions for treating disorders

Also Published As

Publication number	Publication date
BRPI1009381B1 (pt)	2020-04-14
US20120295924A1 (en)	2012-11-22
SG184767A1 (en)	2012-10-30
SI2634191T1 (sl)	2015-04-30
CA2756535A1 (en)	2010-09-30
EP2411395B1 (en)	2013-05-29
CN103755720A (zh)	2014-04-30
ZA201107650B (en)	2012-07-25
AU2010227230B2 (en)	2015-11-26
BRPI1009381A2 (pt)	2016-06-21
EP2411396A2 (en)	2012-02-01
EP2634191B1 (en)	2014-12-24
HUE024538T2 (hu)	2016-01-28
AU2010227225A2 (en)	2011-10-06
EA201190138A1 (ru)	2013-05-30
IL215175A0 (en)	2011-12-29
AU2010227225A1 (en)	2011-09-15
SI2411395T1 (sl)	2013-07-31
US8987278B2 (en)	2015-03-24
ES2424341T3 (es)	2013-10-01
US9474758B2 (en)	2016-10-25
US20120178766A1 (en)	2012-07-12
CN103755720B (zh)	2016-07-06
ES2532386T3 (es)	2015-03-26
BRPI1013705A2 (pt)	2016-04-05
US20130289054A1 (en)	2013-10-31
KR20120004422A (ko)	2012-01-12
SI2411396T1 (sl)	2013-07-31
BRPI1009381B8 (pt)	2021-05-25
CN102361874A (zh)	2012-02-22
AU2010227230A2 (en)	2011-10-27
DK2411396T3 (da)	2013-08-05
IL215177A (en)	2014-01-30
PT2411396E (pt)	2013-06-06
US20150150876A1 (en)	2015-06-04
HK1166073A1 (en)	2012-10-19
IL215177A0 (en)	2011-12-29
WO2010109334A2 (en)	2010-09-30
KR20110128898A (ko)	2011-11-30
AP2011005889A0 (en)	2011-10-31
CA2756536C (en)	2015-10-06
JP2012521407A (ja)	2012-09-13
PE20120775A1 (es)	2012-06-27
CA2756536A1 (en)	2010-09-30
JP5612070B2 (ja)	2014-10-22
ZA201107649B (en)	2012-07-25
DK2411395T3 (da)	2013-08-05
PT2634191E (pt)	2015-03-04
DK2634191T3 (en)	2015-03-23
US8507503B2 (en)	2013-08-13
SG174398A1 (en)	2011-10-28
SG174404A1 (en)	2011-10-28
KR101524337B1 (ko)	2015-05-29
IL215175A (en)	2014-01-30
PL2411395T3 (pl)	2013-10-31
SG184769A1 (en)	2012-10-30
PE20120834A1 (es)	2012-07-25
HK1166074A1 (en)	2012-10-19
ES2424342T3 (es)	2013-10-01
PT2411395E (pt)	2013-06-06
CN102361877A (zh)	2012-02-22
WO2010109334A3 (en)	2010-11-25
JP2012521406A (ja)	2012-09-13
CN102361877B (zh)	2014-05-07
AU2010227230A1 (en)	2011-09-22
PL2634191T3 (pl)	2015-06-30
EP2411395A1 (en)	2012-02-01
MX2011009822A (es)	2012-01-25
EA201190139A1 (ru)	2012-03-30
EA022029B1 (ru)	2015-10-30
WO2010109329A1 (en)	2010-09-30
PL2411396T3 (pl)	2013-10-31
EP2411396B1 (en)	2013-05-29
EP2634191A1 (en)	2013-09-04

Publication	Publication Date	Title
AP2948A (en)	2014-07-31	Thienopyrmidinedione derivatives as TRPA1 modulators
HK1166081A1 (en)	2012-10-19	Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
AP3280A (en)	2015-05-31	Fused pyrimidine-dione derivatives as TRPA1 modulators
HK1173142A1 (en)	2013-05-10	N1-sulfonyl-5-fluoropyrimidinone derivatives n1--5-
HK1172893A1 (en)	2013-05-03	5-fluoropyrimidinone derivatives 5-
IL215169A0 (en)	2011-12-29	Isoxazole -pyridine derivatives as gaba modulators
IL216007A0 (en)	2012-01-31	Isoxazole-pyridine derivatives
IL215109A0 (en)	2011-12-29	Isoxazole-pyridazine derivatives
IL214941A0 (en)	2011-11-30	Isoxazole-pyrazole derivatives
IL213927A0 (en)	2011-07-31	Deoxyactagardine derivatives
HK1172894A1 (en)	2013-05-03	N1-acyl-5-fluoropyrimidinone derivatives n1--5-
HK1169623A1 (en)	2013-02-01	Pyrazinooxazepine derivatives
EP2512482A4 (en)	2013-05-22	DERIVATIVES OF 2-ALDOXIMINO-5-FLUOROPYRIMIDINE
GB0921967D0 (en)	2010-02-03	Novel Aryloxyanilide Derivatives
HK1173134A1 (en)	2013-05-10	Substituted halophenoxybenzamide derivatives
IL213262A0 (en)	2011-07-31	Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en)	2009-08-26	Indopyl-pyridone derivatives
AP2011005883A0 (en)	2011-10-31	Furopyrimidinedione derivatives as TRPA1 modulators.